Q1 2024 Earnings Estimate for Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Issued By William Blair

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Analysts at William Blair raised their Q1 2024 earnings per share (EPS) estimates for shares of Zevra Therapeutics in a research note issued on Tuesday, April 16th. William Blair analyst T. Lugo now expects that the company will post earnings per share of ($0.51) for the quarter, up from their previous forecast of ($0.52). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.65) per share. William Blair also issued estimates for Zevra Therapeutics’ Q3 2024 earnings at ($0.44) EPS, Q4 2024 earnings at ($0.36) EPS, FY2024 earnings at ($1.73) EPS, Q1 2025 earnings at ($0.29) EPS, Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.17) EPS, Q4 2025 earnings at ($0.10) EPS and FY2025 earnings at ($0.77) EPS.

Several other equities research analysts also recently weighed in on ZVRA. Maxim Group increased their price target on Zevra Therapeutics from $12.00 to $18.00 and gave the stock a “buy” rating in a report on Tuesday, April 2nd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zevra Therapeutics in a report on Monday, April 1st. Finally, HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of Zevra Therapeutics in a report on Wednesday, April 3rd. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $19.50.

Zevra Therapeutics Price Performance

NASDAQ:ZVRA opened at $4.52 on Thursday. The firm has a market capitalization of $196.30 million, a price-to-earnings ratio of -3.50 and a beta of 1.81. Zevra Therapeutics has a 1 year low of $3.89 and a 1 year high of $7.28. The business has a 50 day simple moving average of $5.85 and a 200-day simple moving average of $5.36. The company has a debt-to-equity ratio of 0.08, a current ratio of 1.18 and a quick ratio of 1.18.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Nantahala Capital Management LLC increased its holdings in Zevra Therapeutics by 6.3% during the 4th quarter. Nantahala Capital Management LLC now owns 2,453,405 shares of the company’s stock worth $16,070,000 after purchasing an additional 145,189 shares during the period. Vanguard Group Inc. increased its holdings in shares of Zevra Therapeutics by 2.0% in the 4th quarter. Vanguard Group Inc. now owns 1,645,140 shares of the company’s stock valued at $10,776,000 after acquiring an additional 32,639 shares during the period. Janney Montgomery Scott LLC increased its holdings in shares of Zevra Therapeutics by 1.3% in the 4th quarter. Janney Montgomery Scott LLC now owns 683,431 shares of the company’s stock valued at $4,476,000 after acquiring an additional 9,062 shares during the period. Retirement Planning Co of New England Inc. purchased a new position in shares of Zevra Therapeutics in the 3rd quarter valued at $1,674,000. Finally, Northern Trust Corp increased its holdings in shares of Zevra Therapeutics by 11.3% in the 4th quarter. Northern Trust Corp now owns 301,066 shares of the company’s stock valued at $1,972,000 after acquiring an additional 30,624 shares during the period. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc, a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.